文献速递头颈部肿瘤放疗放疗物理与技术

1.5T MR-Linac头颈癌每日MR引导自适应放疗的前瞻性可行性研究

Initial Feasibility and Clinical Implementation of Daily MR-Guided Adaptive Head and Neck Cancer Radiation Therapy on a 1.5T MR-Linac System: Prospective R-IDEAL 2a/2b Systematic Clinical Evaluation of Technical Innovation.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-12-16

本研究前瞻性纳入10例头颈癌患者,在1.5T/7MV MR-Linac上实施每日自适应放疗,其中6例仅用ATP工作流,4例ATP联合1次离线adapt-to-shape再计划。结果显示随机误差等中心偏移在x、y、z方向分别为M=-0.3、0.7、0.1 mm,Σ=3.3、2.6、1.4 mm,σ=1.7、2.9、1.0 mm;γ通过率中位数99.9%(90.9%-100%)。结论认为该工作流安全可行,实际剂量与计划剂量一致。

要点

  • 每日MR引导自适应放疗在头颈癌中安全可行
  • γ通过率中位数99.9%,剂量学质量高
  • CTV累计剂量与参考计划差异在-0.61%至1.78%之间

核心结论

  • 1.5T MR-Linac上基于在线ATP工作流的每日自适应放疗对头颈癌安全且临床可行,实际投照剂量与计划剂量一致。

研究设计与样本

  • 前瞻性研究,纳入10例头颈癌患者接受每日自适应放疗,6例仅用ATP工作流,4例ATP联合1次离线adapt-to-shape再计划。
  • 使用定制固定面具评估摆位变异性,计算等中心偏移的平均系统误差M、系统误差标准差Σ和随机误差标准差σ。
  • 用柱状二极管阵列以3%/3 mm γ标准行质量保证,并汇总每例患者自适应计划与参考计划剂量比较。

主要发现

  • x、y、z方向等中心偏移的随机误差分别为M=-0.3、0.7、0.1 mm,Σ=3.3、2.6、1.4 mm,σ=1.7、2.9、1.0 mm。
  • γ通过率中位数99.9%(范围90.9%-100%)。
  • 参考计划与汇总计划剂量差异:临床靶区为-0.61%至1.78%,危及器官为-11.74%至8.11%。
  • 危及器官剂量增加超过2%仅见于3例,每例仅涉及一个危及器官。
  • 所有病例至少有2次分次出现1个及以上约束违反,但汇总计划中几乎所有约束仍满足。

关键数值与推荐

  • γ分析采用3%/3 mm标准,通过率中位数99.9%(90.9%-100%)。
  • 临床靶区剂量差异范围为-0.61%至1.78%,危及器官剂量差异范围为-11.74%至8.11%。

临床怎么用

  • 头颈癌每日MR引导自适应放疗可采用在线ATP工作流,安全可行且剂量学一致。
  • 尽管单次分次可能出现约束违反,汇总计划剂量仍多能满足约束,支持该工作流临床实施。

局限性

  • 样本量仅10例,其中4例联合离线adapt-to-shape再计划,结果需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This prospective study is, to our knowledge, the first report of daily adaptive radiation therapy (ART) for head and neck cancer (HNC) using a 1.5T magnetic resonance imaging-linear accelerator (MR-linac) with particular focus on safety and feasibility and dosimetric results of an online rigid registration-based adapt to position (ATP) workflow. METHODS AND MATERIALS: Ten patients with HNC received daily ART on a 1.5T/7MV MR-linac, 6 using ATP only and 4 using ATP with 1 offline adapt-to-shape replan. Setup variability with custom immobilization masks was assessed by calculating the mean systematic error (M), standard deviation of the systematic error (Σ), and standard deviation of the random error (σ) of the isocenter shifts. Quality assurance was performed with a cylindrical diode array using 3%/3 mm γ criteria. Adaptive treatment plans were summed for each patient to compare the delivered dose with the planned dose from the reference plan. The impact of dosimetric variability between adaptive fractions on the summation plan doses was assessed by tracking the number of optimization constraint violations at each individual fraction. RESULTS: The random errors (mm) for the x, y, and z isocenter shifts, respectively, were M = -0.3, 0.7, 0.1; Σ = 3.3, 2.6, 1.4; and σ = 1.7, 2.9, 1.0. The median (range) γ pass rate was 99.9% (90.9%-100%). The differences between the reference and summation plan doses were -0.61% to 1.78% for the clinical target volume and -11.74% to 8.11% for organs at risk (OARs), although an increase greater than 2% in OAR dose only occurred in 3 cases, each for a single OAR. All cases had at least 2 fractions with 1 or more constraint violations. However, in nearly all instances, constraints were still met in the summation plan despite multiple single-fraction violations. CONCLUSIONS: Daily ART on a 1.5T MR-linac using an online ATP workflow is safe and clinically feasible for HNC and results in delivered doses consistent with planned doses.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. McDonald BA, Vedam S, Yang J, et al. Initial Feasibility and Clinical Implementation of Daily MR-Guided Adaptive Head and Neck Cancer Radiation Therapy on a 1.5T MR-Linac System: Prospective R-IDEAL 2a/2b Systematic Clinical Evaluation of Technical Innovation. Int J Radiat Oncol Biol Phys. 2020. PMID: 33340604. doi:10.1016/j.ijrobp.2020.12.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。